TrialThe Lancet. Oncology2021

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.

Chung-Han Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.